The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Curaleaf’s unproven claims that CBD treats cancer, Alzheimer’s, chronic pain draws FDA warning

| | July 30, 2019

The company Curaleaf claims that it has developed products that can treat a slew of the most formidable conditions found in humans, including cancer, Alzheimer’s, Parkinson’s, depression, opioid withdrawal, chronic pain, anxiety, post-traumatic stress disorder (PTSD), and attention deficit/hyperactivity disorder (ADHD). 

And just one ingredient in all of its products is responsible for these remarkable medical breakthroughs: the cannabis-derived compound cannabidiol (CBD).

Sadly, those claims are not backed by evidence.

[July 23] the Food and Drug Administration announced that it sent Curaleaf a warning letter for illegally selling unapproved drugs and making unsubstantiated treatment claims.

Such claims that CBD products can treat serious diseases and conditions, “can put patients and consumers at risk by leading them to put off important medical care,” Acting FDA Commissioner Ned Sharpless said in a statement. “Additionally, there are many unanswered questions about the science, safety, effectiveness, and quality of unapproved products containing CBD.”

As for Curaleaf, the company said it is “committed to the highest standards of quality and compliance and will work collaboratively with the FDA to resolve all issues addressed in the agency’s letter.” It has 15 working days to do so.

Read full, original post: A cure for cancer, Alzheimer’s, depression? FDA smacks down wild CBD claims

Related article:  23andMe study probes links between cannabis use and schizophrenia
The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend